NCT02523976View on ClinicalTrials.gov

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2015

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

Acute,Leukemia, Lymphoid

Interventions

DRUG

Dasatinib

Second-generation tyrosine kinase inhibitor

DRUG

prednisone

DRUG

cyclophosphamide

DRUG

daunorubicin

DRUG

vincristine

DRUG

cytarabine

DRUG

mercaptopurine

DRUG

methotrexate

DRUG

dexamethasone

DRUG

mitoxantrone

DRUG

etoposide

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

autologous hematopoietic stem cell transplantation

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT02523976 - Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter